Nalbufine Hcl Orpha (Nalbuphine Hydrochloride)

Nalbuphine Hydrochloride, the active ingredient in Nalbufine Hcl Orpha, is an opioid analgesic presented as an injectable solution for intramuscular, intravenous, and subcutaneous use. It is employed to manage moderate to severe acute pain, including post‑operative and obstetric analgesia, in adult patients.

GNH USA supplies Nalbufine Hcl Orpha as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export to multiple regions. This enables reliable access to essential analgesic therapy across diverse healthcare settings.

Nalbufine Hcl Orpha, an opioid analgesic, is indicated for pain conditions that involve the opioid pathway.

Acute severe pain: provides effective analgesia for sudden, intense pain episodes. Post‑operative pain: reduces pain following surgical procedures. Obstetric analgesia: offers pain relief during labor and delivery. Cancer‑related pain: may be used when other opioids are unsuitable. Procedural pain: can be administered for painful diagnostic or therapeutic procedures.

Common Side Effects: - Nausea - Dizziness - Sedation - Sweating - Headache - Constipation

Serious or Rare Side Effects: - Respiratory depression - Hypotension - Urinary retention - Severe allergic reaction (anaphylaxis) - Adrenal insufficiency

Nalbufine Hcl Orpha requires careful clinical monitoring to ensure safe use. - Dose titration: adjust dose based on individual response and pain severity. - Respiratory monitoring: observe patients with compromised ventilation. - Concomitant CNS depressants: avoid excessive sedation. - Pregnancy and lactation: use only if benefits outweigh risks. - Renal/hepatic impairment: consider dose reduction. - Store at below 25°C: keep in original container, protect from moisture and light.

Nalbufine Hcl Orpha may interact with several drug classes; clinicians should review patient medication profiles. Major Interactions (Avoid): - Other opioids: additive respiratory depression. - CNS depressants (benzodiazepines, barbiturates, alcohol): increased sedation and respiratory risk. - MAO inhibitors: risk of severe hypotension and serotonin syndrome. - Potent CYP3A4 inhibitors: may increase nalbuphine levels. Moderate Interactions (Monitor Closely): - CYP3A4 inducers (rifampin, carbamazepine): may reduce effectiveness. - Serotonergic agents (SSRIs, SNRIs): monitor for serotonin syndrome signs. - Antihistamines: may enhance sedation.